News | February 02, 2026
Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Subscribe To Our Newsletter & Stay Updated
